GALVUS MET 50/500 Price

Overview

Welcome to Dwaey, specifically on GALVUS MET 50/500 Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Vildagliptin, Metformin.
GALVUS MET 50/500 is available in the market in concentration 50mg, 500mg/Tablet and in the form of Tablets/Film-coated.

NOVARTIS PHARMA AG is the producer of GALVUS MET 50/500 and it is imported from SWITZERLAND, The most popular alternatives of GALVUS MET 50/500 are listed downward .

Mode Of Action

Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; improves glucose tolerance and lowers both basal and postprandial plasma glucose . Vildagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycaemic control by preventing DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. This increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function.

Indication

• Type 2 DM

Precaution

Lactic acidosis can occur due to Metformin accumulation. If metabolic acidosis is suspected, treatment should be discontinued and the patient should be hospitalized immediately. Patients with renal impairment & hepatic impairment. Serum creatinine should be monitored at least once a year in patients with normal renal function and 2–4 times a year in patients with serum creatinine levels at the upper limit of normal and in elderly patients. Special caution should be exercised in elderly patients where renal function may become impaired (e.g. when initiating antihypertensives, diuretics or NSAIDs). It is recommended that Liver Function Tests (LFTs) are monitored prior to initiation of this drug, at three-monthly intervals in the first year and periodically thereafter.

Side Effects

• Hypoglycaemia
• delayed gastric emptying
• nausea and vomiting. Flu-like symptoms
• headache and dizziness may occur. Potentially Fatal: Stevens-Johnson syndrome.

Contra indication

This combination is contraindicated in patients with known hypersensitivity to Vildagliptin or Metformin Hydrochloride or to any of the excipients. It is contraindicated in patients with renal disease or renal dysfunction, acute myocardial infarction, and septicaemia. It is also contraindicated in patients with congestive heart failure patients and in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. It should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.

Pregnancy and lactation